It is closely associated with tumorigenesis and drug resistance, making it a potential target for oncology drug development. To date, no ROR1-targeting drugs have been marketed. BR111 utilizes ...

Many organizations are now moving from a digital-first to an AI-first philosophy. Does healthcare need a Chief AI Officer?

A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and ...

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.

Investing.com -- AIM ImmunoTech (NYSE: AIM) Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral ...

Aintree’s urgent care and trauma centre contains the hospital’s emergency department, major trauma, critical care services and frailty assessment unit. Planning permission was granted last March to ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

Non-invasive brain stimulation (NIBS) technologies are rapidly gaining prominence as effective tools for both investigating and modulating brain activity.

However, the scope of BCI applications has gradually broadened to include areas such as education, smart homes, virtual ...

Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want ...